- 5 марта 2019
- Brexit, clinical trials, CT, database, EC, EudraCT, IMP, import, investigational medicinal product, legal consequences, notice, sponsor, UK's withdrawal,
In view of the considerable uncertainties, in particular concerning the content of a possible withdrawal agreement, sponsors (both academic researchers and pharmaceutical companies) conducting or planning to conduct clinical trials, as well as investigators and other persons involved in the preparation and conduct of clinical trials in the EU are reminded of legal repercussions, which need to be considered when the United Kingdom becomes a third country.
Subject to any transitional arrangement that may be contained in a possible withdrawal agreement, as of the withdrawal date, the EU rules on clinical trials, and in particular Directive 2001/20/EC no longer apply to the United Kingdom. This has, in particular, the consequences in the following areas:
SUPPLY OF INVESTIGATIONAL MEDICINAL PRODUCTS
ESTABLISHMENT REQUIREMENTS FOR THE SPONSOR OR THE LEGAL REPRESENTATIVE
SUBMISSION OF CLINICAL TRIAL INFORMATION
All details you will find here.